Skip to content

Author

Meixiao Long

We have 1 of 77 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Developing Novel Bispecific T-cell Engager Therapy by Concurrent Targeting GARP on Cancer Cells and Regulatory T cells 2258672

It is demonstrated that elevated GARP expression in human tumors correlates with poor survival and higher relapse rates after first-line therapies after first-line therapies, and the Anti-GARP/CD3 platform holds the promise as a novel therapy of cancer immunotherapy worthy for clinical translation.

Ziyu Wang, Yaa S Amankwah, J. Mandula et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.